Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31371830 | 1.00 | LCK (0.50) | LCKFYNCA12CA1CA2 | |
| SCHEMBL2813599 | 0.85 | KDM4E (0.52) | KDM4EKMT2ATDP1MEN1GLA | |
| SCHEMBL3958112 | 0.85 | LCK (0.55) | LCKFYNCA12CA1CA2 | |
| SCHEMBL30280663 | 0.83 | GABRP (0.52) | KDM4EKMT2ATDP1MEN1GLA | |
| SCHEMBL28347494 | 0.83 | KDM4E (0.50) | KDM4EKMT2ATDP1MEN1GLA | |
| SCHEMBL2810184 | 0.83 | KDM4E (0.50) | KDM4EKMT2ATDP1MEN1GLA | |
| SCHEMBL9081324 | 0.83 | KDM4E (0.55) | LCKFYNCA12CA1CA2 | |
| SCHEMBL4732592 | 0.83 | GABRP (0.52) | KDM4EKMT2ATDP1MEN1GLA | |
| SCHEMBL2807685 | 0.83 | KDM4E (0.50) | KDM4EKMT2ATDP1MEN1GLA | |
| SCHEMBL2537783 | 0.83 | LCK (0.53) | LCKFYNCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| CN-112236431-B | Purinone Compounds and Their Use in the Treatment of Cancer | 阿斯利康(瑞典)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2024-01-30 | — | — | US | disclosed |
| EP-3807278-B1 | PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-08-31 | — | — | EP | disclosed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| EP-3807278-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2021-04-21 | — | — | EP | disclosed |
| CN-112236431-A | Purinone compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |
| US-7304084-B2 | 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304084-B2 | 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304084-B2 | 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SEED, BRIAN | 2007-11-29 | — | — | US | disclosed |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SEED, BRIAN | 2007-11-29 | — | — | US | disclosed |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SEED, BRIAN | 2007-11-29 | — | — | US | disclosed |
| US-20060122248-A1 | Methods of making 6-[(4,5-dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2006-06-08 | — | — | US | disclosed |
| EP-1594862-A1 | METHODS OF MAKING 6- (4,5-DIHYDRO-1H-IMIDAZOL-2-YL)AMINO-&rs qb;-7-METHYL-1H-BENZIMIDAZOLE-4-CARBONITRILE AND ITS PREFERRED SALT FORM | The Board of Regents of the University of Nebraska (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004074279-A1 | METHODS OF MAKING 6-[(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)AMINO-]-7-METHYL-1H-BENZIMIDAZOLE-4-CARBONITRILE AND ITS PREFERRED SALT FORM | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167194-A1 | Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167194-A1 | Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | AGTR2, ALDH1A2, REN | LCK 3625/4885FYN 4597/4885CA12 921/4885 |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | LCK 4182/4885FYN 4776/4885CA12 4596/4885 |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | LCK 4154/4885FYN 4774/4885CA12 4541/4885 |
| US-20070275907-A1 | GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE | SLC5A1, SLC5A2, SLC2A1 | LCK 2041/4885FYN 3050/4885CA12 1821/4885 |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | RECQL, PRPS1, PURB | LCK 4182/4885FYN 4776/4885CA12 4596/4885 |
| US-20060122248-A1 | Methods of making 6-[(4,5-dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | AGTR2, ALDH1A2, REN | LCK 3298/4885FYN 4653/4885CA12 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.